RATIONALE: The role of serotonin (5-HT) in attention is not fully understood yet. OBJECTIVE: We aimed to investigate whether attention is modulated after treatment with escitalopram, a selective serotonin reuptake inhibitor (SSRI). METHODS: We administered 10 mg of escitalopram to 20 healthy subjects in aplacebo-controlled, double-blind cross-over design for 1 day or to another 20 participants for a period of 7 days. Attention was assessed at time of plasma peak escitalopram concentration using the computerised Attention Network Test (ANT), which is a combined flanker and cued reaction time task. RESULTS: The results showed differential effects of serotonergic manipulation on attention depending on sequence of intake. For the acute treatment, we found significant differences between escitalopram and placebo for all warning conditions dependent of sequence of intake: participants receiving escitalopram as first treatment showed significant slower reaction times in all warning conditions as compared with placebo while participants receiving escitalopram as second treatment showed significant faster reaction times as compared with placebo. For the sub-chronic treatment, we found significant differences between escitalopram and placebo depending on sequence of intake, but only for the flanker condition: participants receiving escitalopram first had significant slower reaction times in incongruent trials with escitalopram as compared with placebo while participants starting with placebo had significant shorter reaction times in incongruent trials with escitalopram. CONCLUSIONS: Thus, the results showed a differential effect of escitalopram in cognition, especially in attention, and are discussed with regard to an interaction between serotonin and familiarity with the attention test.
RCT Entities:
RATIONALE: The role of serotonin (5-HT) in attention is not fully understood yet. OBJECTIVE: We aimed to investigate whether attention is modulated after treatment with escitalopram, a selective serotonin reuptake inhibitor (SSRI). METHODS: We administered 10 mg of escitalopram to 20 healthy subjects in a placebo-controlled, double-blind cross-over design for 1 day or to another 20 participants for a period of 7 days. Attention was assessed at time of plasma peak escitalopram concentration using the computerised Attention Network Test (ANT), which is a combined flanker and cued reaction time task. RESULTS: The results showed differential effects of serotonergic manipulation on attention depending on sequence of intake. For the acute treatment, we found significant differences between escitalopram and placebo for all warning conditions dependent of sequence of intake: participants receiving escitalopram as first treatment showed significant slower reaction times in all warning conditions as compared with placebo while participants receiving escitalopram as second treatment showed significant faster reaction times as compared with placebo. For the sub-chronic treatment, we found significant differences between escitalopram and placebo depending on sequence of intake, but only for the flanker condition: participants receiving escitalopram first had significant slower reaction times in incongruent trials with escitalopram as compared with placebo while participants starting with placebo had significant shorter reaction times in incongruent trials with escitalopram. CONCLUSIONS: Thus, the results showed a differential effect of escitalopram in cognition, especially in attention, and are discussed with regard to an interaction between serotonin and familiarity with the attention test.
Authors: T Koskinen; S Ruotsalainen; T Puumala; R Lappalainen; E Koivisto; P T Männistö; J Sirviö Journal: Neuropharmacology Date: 2000-01-28 Impact factor: 5.250
Authors: Valery Y Yevtushenko; Alexander I Belous; Yevgenia G Yevtushenko; Sergei E Gusinin; Oleg J Buzik; Tatiana V Agibalova Journal: Clin Ther Date: 2007-11 Impact factor: 3.393
Authors: Lauren D Garfield; David Dixon; Petra Nowotny; Francis E Lotrich; Bruce G Pollock; Sean D Kristjansson; Peter M Doré; Eric J Lenze Journal: Am J Geriatr Psychiatry Date: 2013-09-08 Impact factor: 4.105
Authors: Eric J Lenze; David Dixon; Rose C Mantella; Peter M Dore; Carmen Andreescu; Charles F Reynolds; John W Newcomer; Meryl A Butters Journal: Int J Geriatr Psychiatry Date: 2011-06-17 Impact factor: 3.485
Authors: Eric J Lenze; David Dixon; Petra Nowotny; Francis E Lotrich; Peter M Doré; Bruce G Pollock; Anthony L Hinrichs; Meryl A Butters Journal: Int J Neuropsychopharmacol Date: 2012-04-17 Impact factor: 5.176
Authors: Ulla Knorr; Maj Vinberg; Anders Gade; Per Winkel; Christian Gluud; Jørn Wetterslev; Ulrik Gether; Lars Kessing Journal: Ther Adv Psychopharmacol Date: 2011-10